Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 4
1(25.0%)
N/A
1(25.0%)
4Total
Phase 2(2)
Phase 4(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04759105Phase 2Completed

Efficacy of Intradiscal Injection of Autologous BM-MSC in Worker Patients Affected by Chronic LBP Due to Multilevel IDD

Role: collaborator

NCT05066334Phase 2Recruiting

Efficacy of Intradiscal Injection of Autologous BM-MSC in Subjects With Chronic LBP Due to Multilevel Lumbar IDD

Role: collaborator

NCT04796428Phase 4Unknown

GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial

Role: lead

NCT02690467Not ApplicableUnknown

Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.

Role: lead

All 4 trials loaded